Marco Quarta

Marco Quarta

Company: Rubedo Life Sciences

Job title: CEO & Co-Founder

Bio:

Marco co-founded Rubedo Life Sciences, with the company’s mission aimed to increase healthspan by treating the causes of age-related diseases. The strategy is based on systemic therapies capable of safely targeting across the body specific cell types, such as senescent cells, stem cells or cancer cells.

Marco also co-founded Wetware Concepts, YEBN and Turn Biotechnology. He served as executive board member of the European Federation of Biotechnology. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and in the advisory board at the Center for Healthcare Innovation. He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University.

After a graduate degree in Biotechnology from University of Bologna, he received a PhD in Neuroscience from University of Padua, Italy. After that, he completed a post doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University. He then directed a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital Palo Alto, affiliated with the Stanford School of Medicine. Over 10 years at Stanford, he established a translational program in rejuvenative and regenerative medicine. He is author of 25 peer-reviewed publications in the field of aging, physiology, stem cells and regenerative medicine reported in high-impact scientific journals .

 

Seminars:

Explore Targeted Senolytics: A Higher Selectivity & Safety of Systemic Treatments for Geriatric Syndromes 11:45 am

Examine novel small molecule designs for targeted, safe and systemic senolysis Understand senolytic chronic treatments in geriatric preclinical models with high tolerability amelioration of frailty Discuss improvement of age-dependent stem cell exhaustion and loss of regenerative potential recovery of age-related cognitive decline Investigate platform to develop novel senolytic drugs to treat various age-related diseasesRead more

day: Day Two

Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities 4:30 pm

Examining what we do and do not know about the aging process Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions Analyzing the current R&D landscape for anti-aging therapeutics Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.